This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study to Evaluate the Safety of Chronic Administration of Simulect to Subjects Receiving a First Kidney Transplant (Simulect)

This study has been terminated.
(Investigator left University 04/2010)
Information provided by (Responsible Party):
cynthia gifford, Drexel University Identifier:
First received: June 25, 2009
Last updated: February 9, 2015
Last verified: February 2015
The study is undertaken to explore the safety of using Simulect at monthly dose intervals to reduce the need of high dose/level CNI's such as Prograf.

Condition Intervention Phase
End Stage Renal Disease Drug: basiliximab Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: One-year Exploratory Study to Evaluate the Safety of Partial Replacement of CNI With Chronic Administration of Simulect in de Novo Normal-risk Kidney Transplant Recipients Treated With MPA

Resource links provided by NLM:

Further study details as provided by cynthia gifford, Drexel University:

Primary Outcome Measures:
  • To evaluate the risk of sensitization against the chimeric antibody, Simulect. [ Time Frame: one year ]

Secondary Outcome Measures:
  • To describe the pharmacokinetics of Simulect over the study course. [ Time Frame: one year ]
  • To determine the absolute and relative number of CD25 receptors on T cells at the end of each dosing interval. [ Time Frame: one year ]
  • To assess the difference in calculated and measured GFR. [ Time Frame: one year ]
  • To assess the difference in biopsy proven acute rejection rates and the acute and chronic parameters (chronic allograft injury) on surveillance biopsies. [ Time Frame: one year ]
  • To assess the difference in vital signs and lab abnormalities [ Time Frame: one year ]
  • To determine the difference in incidence and severity of albuminuria/proteinuria [ Time Frame: one year ]
  • To collect safety data on infections and malignancies [ Time Frame: one year ]

Enrollment: 5
Study Start Date: May 2009
Study Completion Date: April 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Standard of care administration with Simulect (basiliximab)being administered as per induction therapy on day of transplant and day 4.
Drug: basiliximab
Simulect 20 mg intravenously day of transplant and day 4
Other Name: Simulect
Experimental: Simulect

Simulect (basiliximab) intravenously day of transplant and day 4.

Chronic Simulect (basiliximab) administration monthly for one year duration.

Concomitant decrease in Prograf administration.

Drug: basiliximab
Simulect (basiliximab) 20mg intravenously day of transplant and day 4 post operatively. Then Monthly administration of Simulect (basiliximab) 40 mg intravenously for one year duration.
Other Name: Simulect (basiliximab)

Detailed Description:
The use of CNI's after kidney transplantation is associated with typical adverse effects such as potential contribution to progressive impairment of renal function, hypertension, and metabolic abnormalities. The study consists of a run-in phase (1 month),and treatment phase (11 months) and safety assessment phase (1 month).

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female 18-75
  • First kidney transplant from a living or deceased donor
  • Receiving CNI and MPA
  • Able to tolerate full dose MPA
  • Calculated glomerular filtration rate >=30ml/min by Cockcroft-Gault equation
  • Able to tolerate renal graft biopsies
  • Provided written, informed consent
  • Females of childbearing potential must have a negative pregnancy test within 48 hours prior to the first Simulect administration

Exclusion Criteria:

  • Known hypersensitivity to Simulect
  • Current preformed PRA>10%
  • Multi organ or second kidney transplant
  • Use of any investigational immunosuppressive drug within 1 month of inclusion
  • Female patients who are pregnant, lactating or of child bearing potential and not practicing two approved methods of birth control
  • Known malignancy or history of malignancy other than excised basal or squamous cell carcinoma of the skin
  • HBV, HCV, or HIV positive patients
  • Current severe infection
  • Receiving an organ from an extended criteria donor per United Network for Organ Sharing (UNOS) guidelines
  • Dialysis dependent one month post transplant
  • Live too far away from the transplant center for adequate follow up
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00928811

United States, Pennsylvania
Drexel University College of Medicine
Philadelphia, Pennsylvania, United States, 19102
Sponsors and Collaborators
Drexel University College of Medicine
Principal Investigator: Mysore Anil S. Kumar, MD Drexel University College of Medicine
  More Information

Responsible Party: cynthia gifford, Research Administrator, Drexel University Identifier: NCT00928811     History of Changes
Other Study ID Numbers: 17718
CHI 621A ( Other Identifier: Drexel )
Study First Received: June 25, 2009
Last Updated: February 9, 2015

Keywords provided by cynthia gifford, Drexel University:
de novo kidney transplant subjects
calcineurin inhibitors

Additional relevant MeSH terms:
Kidney Failure, Chronic
Renal Insufficiency, Chronic
Renal Insufficiency
Kidney Diseases
Urologic Diseases
Antibodies, Monoclonal
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on June 22, 2017